Bob Hugin graduated from Princeton University and earned an MBA from the University of Virginia. He served in the United States Marine Corps as an active duty infantry officer. Hugin spent nearly two decades in high-finance, culminating in a managing director role at J.P. Morgan & Co. Inc. He then transitioned to the biotechnology sector, joining Celgene in 1999 and rising to CEO by 2010. Under his leadership, Celgene's market capitalization grew significantly, though the company faced regulatory issues and criticism for drug pricing. Hugin announced his candidacy for the U.S. Senate seat in New Jersey in 2018.

Bob Hugin's political identity is marked by an intriguing blend of socially progressive views with a traditionally conservative label, suggesting an ideologically flexible approach. His support for legal abortion and gay marriage contrasts sharply with his earlier resistance to diversity in his college fraternity, hinting at a nuanced stance on inclusivity. Despite his self-description as a "moderate" and "independent" Republican, his financial backing and alignment with President Trump indicate a strategic political positioning that balances ideological diversity with party loyalty.